COVID-19 treatment clinical trial underway

By Hudson Institute communications

The first clinical trial of a potential COVID-19 treatment involving a discovery by Hudson Institute researchers received approval in September.

Dr Michael Gantier outlines his covid-19 treatment discovery
Dr Michael Gantier

An end-stage prostate cancer drug will be tested as a treatment in COVID-19 patients in Europe, following a discovery by Dr Michael Gantier and his team that the drug has potent anti-inflammatory activity.

The trial will involve approximately 40 patients in hospitals in Ukraine and Moldova, two countries experiencing high rates of SARS-CoV-2 infection and hospitalisation.

Dr Gantier and his team discovered in laboratory tests that the active ingredient in the anti-cancer drug Veyonda, idronoxil, could block the production of several pro-inflammatory proteins, known as cytokines.

These proteins are involved in the ‘cytokine storm’ or hyper-inflammation that leads to life threatening acute respiratory distress and death from COVID-19. By stopping this reaction, the severity of the infection and any potential long-term impacts of COVID-19 could be reduced.

Contact us

Hudson Institute communications
t: + 61 3 8572 2761

About Hudson Institute

Hudson Institute’ s research programs deliver in five areas of medical need – inflammation, cancer, reproductive health, newborn health, and hormones and health. More

Hudson News

Get the inside view on discoveries and patient stories

“Thank you Hudson Institute researchers. Your work brings such hope to all women with ovarian cancer knowing that potentially women in the future won't have to go through what we have!”

Alana Chantry